1. Home
  2. IBIO vs PYPD Comparison

IBIO vs PYPD Comparison

Compare IBIO & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iBio Inc.

IBIO

iBio Inc.

HOLD

Current Price

$1.31

Market Cap

83.5M

Sector

Health Care

ML Signal

HOLD

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$5.24

Market Cap

71.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBIO
PYPD
Founded
2008
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
71.7M
IPO Year
2009
2014

Fundamental Metrics

Financial Performance
Metric
IBIO
PYPD
Price
$1.31
$5.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$4.75
$12.25
AVG Volume (30 Days)
672.6K
133.5K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
81.71
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$3.06
52 Week High
$3.82
$5.73

Technical Indicators

Market Signals
Indicator
IBIO
PYPD
Relative Strength Index (RSI) 38.13 62.21
Support Level $0.98 $4.15
Resistance Level $1.52 $5.67
Average True Range (ATR) 0.07 0.22
MACD -0.01 0.03
Stochastic Oscillator 29.27 73.27

Price Performance

Historical Comparison
IBIO
PYPD

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: